Broadcasting News

"Good Partner 2," Featuring Kim Hye-yoon, Debuts with Viewership Ratings in the 8% Range

SBS's New Friday-Saturday Drama Sequel to 'Good Partner'

KIM HYUNSIK
2026-11-21 09:16:39
[Edaily Reporter KIM HYUNSIK ] “Good Partner 2” got off to a strong start with viewership ratings in the 8% range.
(Photo = SBS)
(Photo = SBS)
According to Nielsen Korea on the 21st, the nationwide viewership rating for the first episode of SBS’s new Friday-Saturday drama “Good Partner 2,” which aired the previous day, was recorded at 8.4%. This figure is 6.8 percentage points lower than the 15.2% viewership rating recorded by its predecessor, “Doctor X: The Age of the White Mafia” (“Doctor X”), at the end of its run. The first episode of “Doctor X” had a viewership rating of 11.4%.
“Good Partner 2” is a drama centered on lawyer Cha Eun-kyung (played by Jang Na-ra), who heads a law firm specializing in divorce cases. As the sequel to “Good Partner,” which aired in 2024, it introduces a new character: Kang Hye-seong (played by Kim Hye-yoon), a fifth-year lawyer nicknamed the “winning machine.” “Good Partner” began with a 7.8% rating and concluded with a peak viewership of 17.7%.
In the first episode of “Good Partner 2,” Cha Eun-kyung and Kang Hye-sung—who belong to different law firms—faced off in their first courtroom showdown. The two clashed as opposing attorneys in a divorce lawsuit filed by husband Seo Ji-hoon (played by Yoon Park) on the grounds of his wife Park Na-yeon’s (played by Go Won-hee) infidelity. Cha Eun-kyung took note of Kang Hye-sung, who argued tenaciously on behalf of her client Seo Ji-hoon, and hinted at the possibility of recruiting her as a new partner.
Episode 2 of “Good Partner 2” airs tonight at 9:50 p.m. The drama stars Jang Na-ra and Kim Hye-yoon, along with Park Hae-jin, P.O., and Ji Seung-hyun.

Economy

Corporation

IT·Science

Economy

[VC's Pick] Big Money Flows into Smart 'Medical AI and Robotics' Technologies That Replace Human Hands

This week (November 16–20), startups in various fields—including robotics, image analysis, and business platforms—secured investments from venture capital (VC) firms and accelerators (ACs). In particu…
2026-11-21 10:04:03

Corporation

Celltrion Sees Full-Scale Results from Direct Sales in the U.S. … “Projected Operating Profit of 2.4 Trillion Won Next Year”

Celltrion(068270)Forecasts indicate that Celltrion will continue its steep earnings growth as it expands its direct sales performance in the U.S. biosimilar market. Expectations for a revaluation of t…
2026-11-21 06:01:02

IT·Science

Penetrium Bioscience and AprilBio Rally as AriBio-Linked Stocks Diverge [K-Bio Pulse]

South Korean pharmaceutical and biotechnology stocks posted mixed results on November 19, driven by clinical trial developments and expectations regarding their inclusion in major stock indices. Penet…
2026-11-21 08:17:02